To prevent, treat, and cure antiphospholipid antibody (aPL) associated clinical manifestations through high-quality, multicenter, and multidisciplinary clinical research.
To refine and advance the definitions of aPL associated clinical manifestations through international collaboration and data sharing.
Members will work together to create a research alliance that will design and conduct clinical trials, and collect data via an international registry.
A Catalyst for Antiphospholipid March 2011 - The treatment of the serious, potentially fatal autoimmune clotting disorder antiphospholipid syndrome (APS) has, in general, been empiric and based on various approaches to inhibit the clotting system.
Little-Studied Blood Syndrome GainsMarch 15, 2011 - Motivated by the lack of treatment options for patients with antiphospholipid syndrome (APS), rheumatology researchers convened an international committee to address the problem directly.
International Summit HeldNovember 2, 2010 - Antiphospholipid Syndrome (APS) is a condition that may be responsible for up to one-third of strokes in people under age 50, up to one-fifth of all cases of blood clots in large veins, and one-quarter of recurrent miscarriages.
to Stimulate Collaborative Clinical Research on Antiphospholipid Syndrome